Wooley A, Kerr J
J Pharm Technol. 2021; 34(1):28-36.
PMID: 34860984
PMC: 5998465.
DOI: 10.1177/8755122517747295.
Alahmadi A, Alahmadi B, Wahman L, El-Shitany N
Saudi J Biol Sci. 2021; 28(11):6158-6166.
PMID: 34764746
PMC: 8568996.
DOI: 10.1016/j.sjbs.2021.06.066.
Alvarez C, Halm E, Pugh M, McGuire D, Hennessy S, Miller R
Endocrinol Diabetes Metab. 2021; 4(1):e00170.
PMID: 33532612
PMC: 7831229.
DOI: 10.1002/edm2.170.
Shin J, Sang Y, Chang A, Dunning S, Coresh J, Inker L
J Am Soc Nephrol. 2020; 31(8):1847-1858.
PMID: 32660971
PMC: 7460896.
DOI: 10.1681/ASN.2019101119.
Kuan I, Savage R, Duffull S, Walker R, Wright D
Drug Saf. 2019; 42(12):1449-1469.
PMID: 31372935
DOI: 10.1007/s40264-019-00854-x.
Prescription of high-risk medications among patients with chronic kidney disease: a cross-sectional study from the Washington, Wyoming, Alaska, Montana and Idaho region Practice and Research Network.
Guirguis-Blake J, Keppel G, Holmes J, Force R, Kriegsman W, Baldwin L
Fam Pract. 2018; 35(5):589-594.
PMID: 29529172
PMC: 6142720.
DOI: 10.1093/fampra/cmy001.
Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study.
Bell S, Farran B, McGurnaghan S, McCrimmon R, Leese G, Petrie J
BMC Nephrol. 2017; 18(1):163.
PMID: 28526011
PMC: 5437411.
DOI: 10.1186/s12882-017-0579-5.
Prevalence of Metformin Use and the Associated Risk of Metabolic Acidosis in US Diabetic Adults With CKD: A National Cross-Sectional Study.
Kuo C, Yeh H, Chen B, Tsai C, Lin Y, Huang C
Medicine (Baltimore). 2015; 94(51):e2175.
PMID: 26705203
PMC: 4697969.
DOI: 10.1097/MD.0000000000002175.
Diabetes: Metformin and renal insufficiency-is 45, or even 30, the new 60?.
Bloomgarden Z
Nat Rev Endocrinol. 2015; 11(12):693-4.
PMID: 26416220
DOI: 10.1038/nrendo.2015.166.
Metformin initiation and renal impairment: a cohort study in Denmark and the UK.
Christiansen C, Ehrenstein V, Heide-Jorgensen U, Skovbo S, Norrelund H, Sorensen H
BMJ Open. 2015; 5(9):e008531.
PMID: 26338686
PMC: 4563232.
DOI: 10.1136/bmjopen-2015-008531.
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
Saine M, Carbonari D, Newcomb C, Nezamzadeh M, Haynes K, Roy J
BMC Pharmacol Toxicol. 2015; 16:8.
PMID: 25889498
PMC: 4404079.
DOI: 10.1186/s40360-015-0007-z.
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Inzucchi S, Lipska K, Mayo H, Bailey C, McGuire D
JAMA. 2014; 312(24):2668-75.
PMID: 25536258
PMC: 4427053.
DOI: 10.1001/jama.2014.15298.
Personalizing guidelines for diabetes management: twilight or dawn of the expert?.
Paschou S, Leslie R
BMC Med. 2013; 11:161.
PMID: 23841986
PMC: 3716722.
DOI: 10.1186/1741-7015-11-161.
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Lipska K, Bailey C, Inzucchi S
Diabetes Care. 2011; 34(6):1431-7.
PMID: 21617112
PMC: 3114336.
DOI: 10.2337/dc10-2361.
Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes.
Strange P
J Diabetes Sci Technol. 2009; 1(4):540-8.
PMID: 19885117
PMC: 2769634.
DOI: 10.1177/193229680700100412.
Contraindications can damage your health--is metformin a case in point?.
Holstein A, Stumvoll M
Diabetologia. 2005; 48(12):2454-9.
PMID: 16283245
DOI: 10.1007/s00125-005-0026-1.
